The defibrase is effective to improve neurological function and function of daily living for patients with acute cerebral infarction within 12 hours of symptom onset. The efficacy was even better for acute cerebral infarction within 6 hours of onset.

Defibrase ® is the trademark registered by Pentapharm for its Active Pharmaceutical Ingredient (API) Batroxobin, a serine protease. Batroxobin is a thrombin-like enzyme purified from the snake venom of Bothrops moojeni.

2006年4月20日 · In this study, we assessed the efficacy and safety of defibrase on acute cerebral infarction in China. Methods: A search using Chinese hospital knowledge database (CHKD) and MEDLINE database for randomized controlled trials was carried out.

In this study, we assessed the efficacy and safety of defibrase on acute cerebral infarction in China. A search using Chinese hospital knowledge database (CHKD) and MEDLINE database for randomized controlled trials was carried out.

This review, which evaluated the efficacy and safety of defibrase for acute cerebral infarction in China, concluded that defibrase may play a role in inhibiting the progression of stroke and prevent recurrence.

2018年6月22日 · Adults with an acute moderate or severe neurological deficit (pretreatment NIHSS 5–22) suggestive of ischemic origin were eligible for defibrinogen therapy. Defibrinogen therapy could be given...

In our study, the multiple-day dosing regimen of defibrase was applied and mainly aimed to reduce bleeding events, such as sICH. Results showed that the number of defibrase administrations appeared not to be associated with functional success.

Meta--analysis of defibrase in treatment of acute cerebraIi nfarction GUO Yi，ZUO Yan-fang，WANG Qi·zhang，TANG Bing·shan，LI Fu‘kang and SUN Yi Keywords：cembmlinfarction；treatment；meta-analysis；defibrase Background Fibrinogen·depleting agents are promising in the treatment of cerebral ischemic disease．They

2005年9月1日 · The defibrase is effective to improve neurological function and function of daily living for patients with acute cerebral infarction within 12 hours of symptom onset. The efficacy was even better for acute cerebral infarction within 6 hours of onset.

Defibrase therapy based on plasma FIB level can rapidly and effectively lower plasma FIB, reduce neurological impairment and improve the quality of life in patients with ACI.